European Virus Archive goes Global

What European Virus Archive goes Global does

European Virus Archive goes Global (EVA-AISBL) is a Marseille-based international non-profit association (AISBL) founded in 2009 that operates a virtual virology resource infrastructure. It coordinates a network of 22 partner laboratories — 19 EU member state institutions and 3 non-EU institutions — to collect, amplify, characterize, standardize, authenticate, distribute, and track viruses and derived products worldwide. The catalog comprises 2,700+ virus strains and 4,000+ product references spanning human, animal, and plant viruses, with cell lines, insect vectors, detection kits, antibodies, proteins, and cloned nucleic acids as complementary offerings. EVA serves scientific researchers, public health stakeholders, and industrial end-users (diagnostic, antiviral, and vaccine developers), with documented reach to 109 countries during COVID-19 and 2,300+ products distributed globally by June 2021.

The platform backbone is the EVA Portal, a web-based online catalogue with online enquiry, quote generation, MTA signing, and order tracking. Products are graded Platinum/Gold/Silver/Bronze based on a documented quality management system aligned with ISO 20387:2018 (biobanking) and ISO 13485:2016 (medical devices), with strict Nagoya Protocol compliance, BSL-3/BSL-4 handling for high-pathogenicity materials, and IVD-R awareness. The value proposition is rooted in standardization, authentication, and traceability of biological resources that would otherwise be scattered across institutions.

EVA's business model is non-profit: products are supplied at cost or non-profitably to bona fide applicants, supplemented by EU research infrastructure grants. Free Trans-National Access (TNA) under H2020 (until August 15, 2024) and free access via the ISIDORe Horizon Europe project provide grant-subsidized distribution. An Industrial Platform offers pre-negotiated MTAs and dedicated order management for commercial users. Revenue is not disclosed; funding flows from the European Commission rather than private capital.

Name

European Virus Archive goes Global

Legal name

EVA | European Virus Archive - AISBL

Website

https://european-virus-archive.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

European Virus Archive goes Global (EVA-AISBL) is a Marseille-based non-profit operating a virtual network of 22 partner laboratories that collect, characterize, and distribute quality-graded viruses and derived products to scientific researchers, public health authorities, and industrial users across 109 countries.

Ownership category

akta.pro rank

Headquarters

HQ city

Marseille

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Operations, Technology or R&D, Personnel, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Virus and Derived Product Sales: EVA-AISBL is a not-for-profit organization that supplies materials non-profitably or at cost. Partner institutions calculate product prices based on their production costs. Products include viruses, nucleic acids, antibodies, proteins, and detection kits at various price points.
2. Trans-National Access (TNA): Free of charge access to EVA products sponsored by the European Commission under H2020. Eligibility criteria include user groups working in countries other than the supplying institute's location, with priority given to new users in countries without equivalent infrastructure. Limited to 20% for non-EU users unless higher percentage is justified.
3. ISIDORe Project Funding: Certain EVA services can be offered as free access through the ISIDORe project, an EU-funded Horizon Europe initiative uniting 17 European research infrastructures for infectious disease outbreak response.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

Core offering

EVA is a non-profit association that mobilizes a global network of 22 partner laboratories to collect, amplify, characterize, standardize, authenticate, distribute, and track viruses and derived products. It provides researchers and industry with standardized access to more than 4,000 viral references (2,700+ virus strains) through a web-based portal, with quality grading (Platinum/Gold/Silver/Bronze), ISO-aligned biosafety controls, and Nagoya Protocol compliance.

Product overview

The European Virus Archive (EVA) is a non-profit infrastructure offering a single entry point for viral resources through the EVA Portal web-based catalogue. The platform provides access to over 4,100 products including virus strains (2,739), derived products (1,462), cloned nucleic acids, antibodies, proteins, and detection kits. Products are quality-graded (Platinum, Gold, Silver, Bronze) based on characterization standards. The ecosystem includes complementary offerings for cell lines and insect vectors, plus an Industrial Platform for commercial users with tailored MTA terms. EVA operates as a virtual infrastructure connecting 22 partner laboratories across 19 EU member states and 3 non-EU institutions.

Differentiator

Problem solved

Functional benefit

Products and services

• EVA Portal Web-based online catalogue providing a single entry point to viruses, reagents, platforms, protocols, processes, trainings and expertise from all EVA partner laboratories.
• Virus Products Virus strains offered in Platinum, Gold, and Silver quality grades covering human, animal, and plant viruses, with freeze-drying, genomic sequencing, mycoplasma testing, and infectivity quantification criteria.
• Cloned Nucleic Acids cDNA products available in Platinum (fully sequenced), Gold (mutations mentioned), Silver (partly sequenced), and Bronze quality grades.
• Antibodies Monoclonal and polyclonal antibodies offered in Platinum (affinity-purified, characterized by 3+ methods), Gold (2 methods), Silver (1 method), and Bronze grades.
• Viral Proteins Viral proteins available in Platinum (purified >95%, functionally characterized), Gold (purified but not functionally characterized), and Silver grades (unpurified or partly purified).
• Detection Kits Research-use-only detection kits including lyophilized primers and probes for real-time RT-PCR, encapsidated RNA controls, and assay panels for viruses such as Bundibugyo Ebolavirus.
• Industrial Platform Dedicated service for industrial end-users offering pre-negotiated MTAs for diagnostic test R&D, antiviral drug R&D, vaccine R&D, and internal research, with dedicated order management and specific biobank access.
• Trans-National Access (TNA) Program Free transnational access to EVA products sponsored by the European Commission under H2020/Horizon Europe, providing free product access to eligible researchers in countries other than the supplying institute's location.

Quantifiable outcome

• 2300+ products distributed to 109 countries during COVID-19 pandemic by June 2021
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• World Health Organization (WHO)coreStrategic or Co-development Partner · 1 January 2009EVA has cooperated with WHO since 2009 to generate capacities for global distribution of diagnostic materials and protocols during epidemiological emergencies. EVA participates as an active actor under the WHO umbrella during virus outbreaks including MERS-CoV and Ebola.
• World Organisation for Animal Health (WOAH)coreStrategic or Co-development Partner · 1 January 2009EVA maintains close relationships with WOAH as part of its international public health collaboration network, supporting global capacity for outbreak response and diagnostic material distribution.
• Pan American Health Organization (PAHO)coreStrategic or Co-development PartnerEVA has established close relationships with PAHO as part of its extension of network and integration of international organizations involved in public health.
• US Centers for Disease Control and Prevention (CDC)coreStrategic or Co-development PartnerEVA cooperates with CDC since 2009 for global distribution of diagnostic materials and protocols during epidemiological emergencies.
• ISIDORe ProjectcoreStrategic or Co-development PartnerEU-funded Horizon Europe project uniting 17 European research infrastructures to offer integrated services for combating current and future infectious disease outbreaks. EVA services identified within ISIDORe can be offered as free access opportunities.
• German Nagoya Protocol HuBminorGTM or Marketing PartnerCollaboration on ABS (Access and Benefit Sharing) compliance education. EVA provides a 'Nagoya for Newbies' webinar in collaboration with this project. The German Nagoya Protocol HuB provides videos, fact sheets, infographics, and interactive materials on ABS.
• Infravec2 European ConsortiumminorStrategic or Co-development PartnerPartnership to offer insect vectors infected with EVA viruses. EVA collaborates with Infravec2 to provide specific insect vectors to end-users through the Infravec2 web catalogue.
• 22 Partner Laboratories NetworkcoreTechnology or IntegrationInternational network of 22 laboratories including 19 EU member state institutions and 3 non-EU institutions representing extensive range of virological disciplines. Partner laboratories produce, characterize, and distribute viruses and derived products through the EVA catalogue.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• ATCC (American Type Culture Collection): ATCC is the world's largest biorepository of authenticated cell lines, viruses, and microorganisms. It is comparable to EVA in the virology reagent domain but operates as a broad commercial incumbent across all biological materials rather than specialising in virology.
• Pasteur Institute (Biological Resource Centre): The Pasteur Institute maintains a major microbial strain collection (CIP) with global distribution for research and public health. While broader than EVA in scope, its virology resource component is directly comparable.

Emerging players

• Addgene: Addgene is a major non-profit plasmid repository distributing biological research materials globally under similar material-transfer-based economics. It is structurally comparable as a non-profit life-science resource broker, though its focus is plasmids rather than viral reagents.
• Infravec2 Consortium: Infravec2 is an EU-funded consortium offering insect vector infrastructure for arbovirus research, with an explicit partnership with EVA. It is comparable as a complementary, EU-funded, project-based life-science infrastructure rather than a directly competing virology collection.

Direct peers

• Culture Collections (UKHSA/ECACC): Culture Collections, including the European Collection of Authenticated Cell Cultures (ECACC), provides authenticated cell cultures and microbiological reagents to researchers globally, mirroring EVA's role as a public-good life-science resource.
• DSMZ (Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures): DSMZ is a major European microbial and cell culture collection offering authenticated biological resources with rigorous quality criteria. It is one of EVA's closest European peers and a collaborating node within the broader biobanking ecosystem.
• BEI Resources (NIAID): BEI Resources is the NIAID-managed repository for emerging infectious disease reagents. It directly overlaps EVA in distributing authenticated viral and bacterial materials to researchers, with a similar quality-controlled, application-based access model.
• NCTC (National Collection of Type Cultures): NCTC is one of the oldest bacterial and viral reference collections, supplying authenticated cultures for research and public health. Its mission of distributing reference strains underpins diagnostic and surveillance work analogous to EVA.

Regional players

• NITE Biological Resource Center (NBRC): NBRC is Japan's national microbial culture collection, distributing authenticated microorganisms to industry and academia. Its Asia-Pacific focus and fee-for-service model parallel EVA's regional role for Europe.
• CCMD (China Center for Microbial Culture Collection): CCMD maintains China's national microbial culture collection, distributing reference strains primarily within China and Asia. It is structurally similar to EVA but serves a different geographic market.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/evag_eu
• YouTubeyoutube.com/channel/UCU8PTyVd0fHcT5_S83YiWmw
• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/evag?trk=top_nav_home

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about European Virus Archive goes Global